Fluticasone HFA has been added to all BCBSRI commercial formularies as a preferred tier medication. This takes effect with a back date to April 1, 2024. Flovent HFA was no longer available as of January 1, 2024. There is a current manufacturer supply shortage of Asmanex HFA. The decision was made to add the Fluticasone HFA to all commercial formularies to allow for an alternative for an HFA propellant aerosolized delivery. Additionally, Arnuity and Qvar remain on the formulary in the inhaled ICS drug category.